HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma

NCT06187961 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Non-resectable

Interventions

PROCEDURE: Hepatic arterial infusion chemotherapy (HAIC-FOLFOX)
DRUG: Lenvatinib
DRUG: Cadonilimab

Sponsor

Tongji Hospital

Collaborators

Akesobio